Apic Bio, Inc.

Apic Bio, Inc. is a biotechnology company focused on developing innovative gene therapies aimed at treating rare genetic disorders and diseases, utilizing advanced technologies to enhance therapeutic efficacy. Founded in 2017 in Cambridge, US, Apic Bio, Inc. specializes in gene therapy solutions.

The company raised USD 10 mn in November 2018 from unspecified investors, bringing the total amount raised to USD 30. 18 mn. The founder, Christian Mueller, has a history in biotechnology, although no details about previous ventures are provided. Apic Bio, Inc.

develops cutting-edge gene therapies that target rare genetic diseases. Their portfolio includes innovative treatment options designed to correct genetic defects at the molecular level, potentially offering cures for previously untreatable conditions, focusing on patient-centric solutions. Apic Bio, Inc. generates revenue through strategic partnerships and funding for its research and development initiatives.

The revenue model primarily involves securing investments to support the advancement of its gene therapy projects and potential future commercialization of its therapies. Apic Bio, Inc. plans to leverage the USD 10 mn raised in November 2018 to further develop its gene therapy pipeline and bring new products to market. The company aims to expand its reach into European and Asian markets by 2023, targeting partnerships with local biotech firms to facilitate this growth.

Furthermore, the company is focusing on launching new therapies within the next two years, enhancing its product offerings to address a broader range of genetic disorders.